
Opinion|Videos|April 4, 2025
Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an effective CRS management protocol as well as best practices for transitions of care between settings when administering and managing bispecifics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Why is it critical to have standardized protocols in place for managing CRS in patients receiving bispecific antibodies?
- What are the key components of an effective CRS management protocol?
- What are best practices for transitions of care between settings when administering and managing bispecifics?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Monoclonal Antibodies Had Varying Efficacy in Treating MG
5






